NCT01268111

Brief Summary

Healthy subjects with low Vitamin D levels will be randomly assigned to either Vitamin D replacement or placebo for a period of 8 weeks. Insulin sensitivity will be measured before and after the intervention, and the changes will be compared between the two groups. This will help us understand if Vitamin D replacement improves insulin sensitivity. Serum Retinol Binding Protein 4 levels will also be measured to see if changes in insulin sensitivity are mediated by RBP4.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
12

participants targeted

Target at below P25 for phase_1

Timeline
Completed

Started Jan 2011

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 28, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

December 29, 2010

Completed
3 days until next milestone

Study Start

First participant enrolled

January 1, 2011

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2012

Completed
1.2 years until next milestone

Results Posted

Study results publicly available

May 24, 2013

Completed
Last Updated

June 8, 2015

Status Verified

May 1, 2015

Enrollment Period

1.2 years

First QC Date

December 28, 2010

Results QC Date

January 4, 2013

Last Update Submit

May 11, 2015

Conditions

Keywords

vitamin D deficiency, insulin sensitivity

Outcome Measures

Primary Outcomes (1)

  • M Value (Insulin Stimulated Glucose Uptake)

    Insulin stimulated glucose uptake will be measured by glucose clamp studies

    Baseline and at 8 weeks

Study Arms (2)

Vitamin D

EXPERIMENTAL

ERgocalcifoerol 50,000 units q weekly for 8 weeks

Drug: Ergocalciferols

Placebo

PLACEBO COMPARATOR
Drug: Placebo

Interventions

ERgocaclciferol 50,000 units weekly for 8 weeks

Vitamin D

matching placebo

Placebo

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • \. Age 18-60 years 2. No known medical illnesses requiring pharmacotherapy 3. Not on any mineral or vitamin supplements in the last 3 months

You may not qualify if:

  • \. Subjects requiring prompt initiation of pharmacotherapy, such as those with incidentally discovered diabetes mellitus or hypertension.
  • \. Previous administration of glucocorticoids, retinoic acid derivatives, or insulin sensitizers in the preceding 3 months.
  • \. Bariatric surgery or liposuction 4. Unintentional weight loss \>5% of the body weight in last 3 months 5. Chronic smokers (\> 1 pk/d for 10 years) 6. Alcohol use \> 2 drinks/day

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Texas Tech University Health Sciences Center

Odessa, Texas, 79763, United States

Location

Related Publications (1)

  • Simha V, Mahmood M, Ansari M, Spellman CW, Shah P. Effect of vitamin D replacement on insulin sensitivity in subjects with vitamin D deficiency. J Investig Med. 2012 Dec;60(8):1214-8. doi: 10.2310/JIM.0b013e3182747c06.

MeSH Terms

Conditions

Insulin ResistanceVitamin D Deficiency

Interventions

Ergocalciferols

Condition Hierarchy (Ancestors)

HyperinsulinismGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesAvitaminosisDeficiency DiseasesMalnutritionNutrition Disorders

Intervention Hierarchy (Ancestors)

CholestenesCholestanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSterolsVitamin DSecosteroidsMembrane LipidsLipids

Results Point of Contact

Title
A J Vinaya Simha
Organization
Mayo Clinic

Study Officials

  • Vinaya Simha, MD

    Mayo Clinic

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 28, 2010

First Posted

December 29, 2010

Study Start

January 1, 2011

Primary Completion

March 1, 2012

Study Completion

March 1, 2012

Last Updated

June 8, 2015

Results First Posted

May 24, 2013

Record last verified: 2015-05

Locations